Actively Recruiting
Atrophic Gastritis Predicts the Risk of Gastric Cancer: a Prospective Cohort Study
Led by Shanghai Jiao Tong University School of Medicine · Updated on 2024-12-30
2042
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Gastric cancer remains a major cause of cancer-related deaths worldwide, particularly in Eastern Asia. This research focuses on the role of atrophic gastritis and intestinal metaplasia as key risk factors for developing gastric cancer. The study aims to investigate the rate of gastric cancer linked to atrophic gastritis in a high-risk population through a prospective cohort design. Participants will undergo surveillance endoscopies according to their level of gastritis severity classified by the operative link on gastritis assessment (OLGA). Those with OLGA stages 0-I will have endoscopies every 3 to 5 years, OLGA II every 2 to 3 years, and OLGA III-IV annually. This observational approach helps monitor early gastric neoplasms among different risk groups. During the study, participants will be monitored with scheduled endoscopies over several years depending on their OLGA classification. The main outcome measured is the development of early gastric neoplasms, tracked through these follow-up endoscopies. The study spans many years, with ongoing evaluations to understand cancer risk related to atrophic gastritis and mucosal changes.
CONDITIONS
Brief Title
Atrophic Gastritis Predicts the Risk of Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability and willingness to participate in the study and to sign and give informed consent
- Biopsies were collected based on the recommendation of updated Sydney system
You will not qualify if you...
- Under 18 or over 80 years old
- History of gastrectomy
- Severe systemic diseases or malignancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 day
Participants undergo a baseline esophagogastroscopy to assess the severity of atrophic gastritis using the OLGA system.
1 baseline visit (in-person)
Duration - Up to 12 years
Participants undergo follow-up esophagogastroscopies at intervals based on their OLGA stage to monitor for early gastric neoplasm.
Surveillance endoscopies every 1 to 5 years depending on OLGA stage
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China, 200127
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here